Biogen Idec released much anticipated results from a study of a potential Alzheimer’s disease treatment on Friday, showing that it slowed cognitive decline in some patients. In December, the biotechnology company said the developing drug aducanumab reduced a type of plaque in the brain believed to play a key role in the disease and slowed clinical impairment in patients with a mild form of the disease.